Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,800 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 July 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 4MB, 236 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 122 results:
Author Title [ Type(Asc)] Year
Filters: Author is van Staa, T. P.  [Clear All Filters]
Journal Article
Y. Li, Sperrin, M., Ashcroft, D. M., and van Staa, T. P., “Consistency of variety of machine learning and statistical models in predicting clinical risks of individual patients: longitudinal cohort study using cardiovascular disease as exemplar”, Bmj, vol. 371, p. m3919, 2020.
S. Abtahi, Driessen, J. H. M., Burden, A. M., Souverein, P. C., van den Bergh, J. P., van Staa, T. P., Boonen, A., and de Vries, F., “Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study”, Ann Rheum Dis, 2020.
F. de Vries, Setakis, E., and van Staa, T. P., “Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes”, Br J Clin Pharmacol, vol. 70, pp. 429-38, 2010.
T. P. van Staa, Setakis, E., Di Tanna, G. L., Lane, D. A., and Lip, G. Y., “A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice”, J Thromb Haemost, vol. 9, pp. 39-48, 2011.
T. P. van Staa, Leufkens, H. G., Zhang, B., and Smeeth, L., “A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example”, PLoS Med, vol. 6, p. e1000194, 2009.
H. A. van den Ham, Klungel, O. H., Singer, D. E., Leufkens, H. G., and van Staa, T. P., “Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database”, J Am Coll Cardiol, vol. 66, pp. 1851-9, 2015.
M. C. Gulliford, van Staa, T. P., McDermott, L., McCann, G., Charlton, J., and Dregan, A., “Cluster randomized trials utilizing primary care electronic health records: methodological issues in design, conduct, and analysis (eCRT Study)”, Trials, vol. 15, p. 220, 2014.
R. Boggon, van Staa, T. P., Timmis, A., Hemingway, H., Ray, K. K., Begg, A., Emmas, C., and Fox, K. A., “Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction–a hospital registry-primary care linked cohort (MINAP-GPRD)”, Eur Heart J, vol. 32, pp. 2376-86, 2011.
T. P. van Staa, Geusens, P., Bijlsma, J. W., Leufkens, H. G., and Cooper, C., “Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis”, Arthritis Rheum, vol. 54, pp. 3104-12, 2006.
T. P. van Staa, Cooper, C., Leufkens, H. G., and Bishop, N., “Children and the risk of fractures caused by oral corticosteroids”, J Bone Miner Res, vol. 18, pp. 913-8, 2003.
C. J. Edwards, Arden, N. K., Fisher, D., Saperia, J. C., Reading, I., van Staa, T. P., and Cooper, C., “The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database”, Rheumatology (Oxford), vol. 44, pp. 1394-8, 2005.
E. Setakis, Leufkens, H. G., and van Staa, T. P., “Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib”, Arthritis Rheum, vol. 59, pp. 1105-11, 2008.
A. Lalmohamed, Bazelier, M. T., van Staa, T. P., Uitdehaag, B. M., Leufkens, H. G., de Boer, A., and de Vries, F., “Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study”, Eur J Neurol, vol. 19, pp. 1007-14, 2012.
R. Williams, van Staa, T. P., Gallagher, A. M., Hammad, T., Leufkens, H. G. M., and de Vries, F., “Cancer recording in patients with and without type 2 diabetes in the Clinical Practice Research Datalink primary care data and linked hospital admission data: a cohort study”, BMJ Open, vol. 8, p. e020827, 2018.
R. Boggon, van Staa, T. P., Chapman, M., Gallagher, A. M., Hammad, T. A., and Richards, M. A., “Cancer recording and mortality in the General Practice Research Database and linked cancer registries”, Pharmacoepidemiol Drug Saf, vol. 22, pp. 168-75, 2013.
V. Abbing-Karahagopian, Kurz, X., de Vries, F., van Staa, T. P., Alvarez, Y., Hesse, U., Hasford, J., Dijk, L., de Abajo, F. J., Weil, J. G., Grimaldi-Bensouda, L., Egberts, A. C., Reynolds, R. F., and Klungel, O. H., “Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project”, Curr Clin Pharmacol, vol. 9, pp. 130-8, 2014.
S. R. Pye, Sheppard, T., Joseph, R. M., Lunt, M., Girard, N., Haas, J. S., Bates, D. W., Buckeridge, D. L., van Staa, T. P., Tamblyn, R., and Dixon, W. G., “Assumptions made when preparing drug exposure data for analysis have an impact on results: An unreported step in pharmacoepidemiology studies”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 781-788, 2018.
T. P. van Staa, Bishop, N., Leufkens, H. G., and Cooper, C., “Are inhaled corticosteroids associated with an increased risk of fracture in children?”, Osteoporos Int, vol. 15, pp. 785-91, 2004.
C. Klop, Gibson-Smith, D., Elders, P. J., Welsing, P. M., Leufkens, H. G., Harvey, N. C., Bijlsma, J. W., van Staa, T. P., and de Vries, F., “Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010”, Osteoporos Int, vol. 26, pp. 1919-28, 2015.
V. Abbing-Karahagopian, Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G., Slattery, J., Alvarez, Y., Miret, M., Gil, M., Oliva, B., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlienger, R. G., de Groot, M. C., Klungel, O. H., van Staa, T. P., van Dijk, L., Egberts, A. C., Gardarsdottir, H., and De Bruin, M. L., “Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications”, Eur J Clin Pharmacol, vol. 70, pp. 849-57, 2014.
T. P. van Staa, Travis, S., Leufkens, H. G., and Logan, R. F., “5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study”, Gastroenterology, vol. 126, pp. 1733-9, 2004.
T. P. van Staa, Card, T., Logan, R. F., and Leufkens, H. G., “5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study”, Gut, vol. 54, pp. 1573-8, 2005.
[Page last reviewed 5 July 2021]